Welcome to the Indiana Hemophilia & Thrombosis Center.

The IHTC was established in 1998 by Amy D. Shapiro, M.D., the center's co-medical director and pediatric hematologist, and Anne Greist, M.D., the center's co-medical director and adult hematologist. The center is located at the St. Vincent Hospital campus in Indianapolis, Indiana. Patient care, research and education are the focus of the center. Yet at the heart of all we do is patient care, as our mission statement indicates:

The Indiana Hemophilia & Thrombosis Center Inc. is committed to providing the highest quality comprehensive healthcare services to patients with bleeding and clotting disorders, and to their families.

Employment Opportunities

Click here to view current open positions.

School Educator Program

Click here to watch our educational videos designed for school staff members

IHTC News:

IHTC is Moving!

As of September 8, the IHTC has a new home and address: 8326 Naab Rd, Indianapolis, IN 46260. For more information about our new home, visit www.ihtc.org/ihtcmove.

Biogen Idec’s ELOCTATE™ is now approved by the FDA for hemophilia A (factor VIII deficiency).

The US Food and Drug Administration (FDA) has approved Biogen Idec’s ELOCTATE™ for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A (factor VIII deficiency). Visit the National Hemophilia Foundation’s website for more details.

The IHTC was named a Top Workplace for the 5th year in a row! Read on for more details.

Yesterday, April 20th, the Indianapolis Star published “Top Workplaces 2014” – a list of the best places to work in the Central Indiana region. The IHTC has been named to the list for the 5th year in a row! The evaluation for the Top Workplaces program is based on feedback from an employee survey completed […]

First long-acting factor IX concentrate approved for patients with hemophilia B!

The U.S. Food and Drug Administration has approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have hemophilia B.